Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. Mai 2026 15:47 ET | Quelle: Robbins LLP

Robbins LLP Encourages Super Micro Computer, Inc. Stockholders with Large Losses to Contact the Firm to Learn How SMCI Failed to Disclose its Violations of U.S. Export Control Laws

Robbins LLP is Investigating Allegations that Super Micro Computers, Inc. (SMCI) Failed to Disclose Violations of U.S. Export Control Laws
05. Mai 2026 15:09 ET | Quelle: Robbins LLP

The Lead Plaintiff Deadline for the PSIX Class Action is May 19, 2026 - Contact Robbins LLP for Information About Your Rights Against Power Solutions International, Inc.

Robbins LLP is Investigating Allegations that Power Solutions International, Inc. (PSIX) Misled Investors Regarding its Business Prospects
01. Mai 2026 13:50 ET | Quelle: Robbins LLP

BW Stockholders Have Rights – If you Lost Money Investing in Babcock & Wilcox Enterprises Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Babcock & Wilcox Enterprises, Inc. (BW) Misled Investors Regarding its Business Prospects
28. April 2026 12:28 ET | Quelle: Robbins LLP

Monday.com Class Action Reminder – Robbins LLP Encourages MNDY Investors to Contact the Firm for Information About Their Rights

Robbins LLP is Investigating Allegations that monday.com Ltd. (MNDY) Misled Investors Regarding its Business Prospects
28. April 2026 12:02 ET | Quelle: Quoin Pharmaceuticals, Inc.

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia...
28. April 2026 08:30 ET | Quelle: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia...
21. April 2026 14:44 ET | Quelle: Robbins LLP

Robbins LLP Encourages GEMI Stockholders to Contact the Firm for Information About the Class Action Against Gemini Space Station, Inc.

Robbins LLP is investigating whether Gemini Space Station (GEMI) misled investors in its IPO offering disclosures.
21. April 2026 14:34 ET | Quelle: Robbins LLP

Robbins LLP Urges ATRA Stockholders to Contact the Firm for Information About the Class Action Against Atara Biotherapeutics, Inc.

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
20. April 2026 16:32 ET | Quelle: Robbins LLP

ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Aldeyra Therapeutics, Inc. (ALDX) Misled Investors Regarding its Lead Drug Candidate
20. April 2026 16:29 ET | Quelle: Robbins LLP

IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that ImuunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate

Nächste Seite